Dr Reddy's Laboratories Ltd has announced that it has introduced for the first time in India, a European research product Doxofylline, a novel second-generation xanthine bronchodilator. The company has introduced this product under license agreement from Kent Union Ltd, Hong Kong, and marketing cooperation with Netherlands-based pharma company, Eurodrug Laboratories BV.

Doxofylline has been introduced under the brand name "Doxobid" and will be available in a special pack of 10's in 400mg dosage. Doxobid is meant to treat patients suffering from asthma chronic obstructive pulmonary disease (COPD).

Launched nationwide, Doxobid will further help the Dr Reddy's to consolidate its position in the asthma and COPD segment as it has been moving towards strengthening its respiratory portfolio. The total market of methyl xanthines (combinations and plain) is estimated at around at Rs60 crore.